Sun Pharmaceutical Industries Ltd on Tuesday announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for its clascoterone cream, Winlevi. Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Winlevi will be available in Australia from June 2024, the company said in a regulatory filing on March 19.
As stated by Hellen de Kloet, Business Head – Western Europe, Australia and New Zealand,
Sun Pharma, "Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi's novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne."
"We are very pleased that Winlevi will soon be available to patients in Australia. This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions," said Diana Harbort, President of the Dermatology Division of Cosmo.
Shares of Sun Pharmaceutical Industries Ltd settled 1.37% higher at ₹1,569.35 apiece on the NSE on Monday. The stock has gained 25% so far in 2024.
First Published: Mar 19, 2024 8:59 AM IST
